13th European ISSX Meeting Program

Welcome to Glasgow!

Dear Colleagues and Friends,

On behalf of the International Society for the Study of Xenobiotics (ISSX), it is with pleasure that we welcome you to the 13th European ISSX Meeting. The Meeting Organising Committee, symposia chairs, and speakers have carefully designed a programme to address key research topics including: PBPK Modeling, Stem Cell Technology Developments and their Application to Drug Metabolism and Drug Safety, the Role of Drug Transporters, Epigenomics in Drug Metabolism and Disease, Mass Spectrometry of Small Molecules, and much more.

The meeting begins with four short courses on mass spectrometry, stem cell derived tissues, and pharmacokinetic modeling. These courses are followed by an opening keynote lecture presented by Professor Sir Philip Cohen of the University of Dundee and our Opening Welcome Reception with exhibitors. The meeting additionally features twelve scientific symposia and additional plenary sessions. The European Scientific Achievement Award and the European New Investigator Award in Honor of Karl J. Netter will be presented to this year's award winners on Wednesday, June 24 at 16:15. The abstract poster sessions will cover a wide range of contemporary research topics and winners of the ISSX Poster Awards Competition will be announced on Thursday, June 25 at 12:30. Complementing the meeting, top suppliers to the scientific community will present their products and services during the meeting exhibition hours each day.

The premier social event for this meeting is a dinner and ceilidh at the Glasgow Old Fruitmarket on Wednesday, June 24 at 18:30. This unique setting is the perfect backdrop to enjoy a meal and entertainment with friends and colleagues. Tickets may still be available. Please enquire at the registration counter in the Level 2 Foyer.

When not attending the sessions, we hope you will explore the charming and vibrant city of Glasgow. There is a diverse array of cultural and entertainment options available along with an excellent dining scene. Supported by a great transportation network, meeting attendees and accompanying guests can take in all that this unique and beautiful city has to offer.

Welcome and enjoy the meeting!

Sincerely,

Roland Wolf, PhD, OBE and Ann Daly, PhD University of Dundee Newcastle University 13th European ISSX Meeting Co-Chairs

Table of Contents

Schedule Overview

General Information

Scientific Program

Poster Information

Exhibitor Directory

2

8 – 9

10 – 14

15 – 16

19 – 22

Inside Front Cover Welcome from 13th European ISSX Meeting Co-Chairs, Ann Daly and Roland Wolf

2 Schedule Overview

3 13th European ISSX Meeting Committees

4 Upcoming ISSX Meetings

5 ISSX Leadership and Staff

6 – 7 European ISSX Awards

8 – 9 General Information and

Glasgow City Map

10 – 14 Scientific Program

15 – 16 Poster Information

17 Industry-Sponsored Symposium and ISSX Sponsors

18 ISSX Meeting Dinner and Ceilidh

19 – 22 Exhibitor Directory

22 – 24 Notes Pages

Inside Back Cover Technology and Innovation Centre Floor Plan

Schedule Overview

Monday, June 22, 2015 08:00 – 19:00 LEVEL 2 FOYER Meeting Registration Open

13:00 – 17:00 LEVELS 2 and 3 FOYER Exhibitor Set-Up

09:00 – 12:30 AUDITORIUMS A and B/C Concurrent Morning Short Courses 1 and 2*

12:30 – 13:30 CONFERENCE ROOMS 6 and 7 Lunch for All Short Course Registrants

13:30 – 17:00 AUDITORIUMS A and B/C Concurrent Afternoon Short Courses 3 and 4*

17:45 – 18:00 AUDITORIUM A/B/C Opening Session

18:00 – 18:45 AUDITORIUM A/B/C Opening Keynote Lecture

18:45 – 20:45 LEVELS 2 and 3 FOYER Opening Welcome Reception / Meet the Exhibitors

Tuesday, June 23, 2015 07:30 – 17:00 LEVEL 2 FOYER Meeting Registration Open

07:30 – 09:00 LEVEL 2 FOYER Finalist Awards Poster Set-Up

07:30 – 09:00 LEVEL 3 FOYER and ROOM 4/5 General Poster Set-Up

07:45 – 08:45 AUDITORIUM A Industry-Sponsored Symposium: Quotient Bioresearch

09:00 – 12:00 AUDITORIUMS A and B/C Parallel Symposia 1 and 2

10:30 – 11:00 LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters

12:00 – 13:30 LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch / View Posters

12:00 – 13:00 LEVEL 2 FOYER Finalist Awards Posters A1 through A6 Presented

12:30 – 13:30 LEVEL 3 FOYER and ROOM 4/5 General Posters P1 through P85 Presented




18:30 – 19:30 GLASGOW CITY CHAMBERS Civic Reception*

19:30 – 22:00 WAXY O’CONNOR’S New Investigators Reception*

Wednesday, June 24, 2015 08:00 – 17:00 LEVEL 2 FOYER Meeting Registration Open




12:00 – 13:00 LEVEL 2 FOYER Finalist Awards Posters A7 through A12 Presented

12:30 – 13:30 LEVEL 3 FOYER and ROOM 4/5 General Posters P86 through P166 Presented



16:15 – 17:30 AUDITORIUM A/B/C Presentation of ISSX Awards

18:30 – 22:00 OLD FRUITMARKET Meeting Dinner and Ceilidh*

Thursday, June 25, 2015 08:00 – 17:00 LEVEL 2 FOYER Meeting Registration Open



12:30 – 13:00 AUDITORIUM A/B/C Presentation of ISSX Poster Awards

13:00 – 15:00 AUDITORIUM A/B/C Plenary Session

15:00 – 15:45 AUDITORIUM A/B/C Closing Plenary Lecture

15:45 – 16:00 AUDITORIUM A/B/C Closing Remarks

*These events require a ticket. If you are interested in attending, please inquire at the registration counter.

2

13th European ISSX Meeting Committees

Meeting Organising Committee Chairs

Ann Daly, PhD, Newcastle University

Roland Wolf, PhD, University of Dundee

Meeting Organising Committee

John Hayes, PhD, University of Dundee

Brian Houston, PhD, University of Manchester

Neil Kitteringham, PhD, University of Liverpool

Michael McMahon, PhD, University of Dundee

Richard Meehan, PhD, University of Edinburgh

Munir Pirmohamed, PhD, University of Liverpool

Colin Suckling, PhD, University of Strathclyde

Geoff Tucker, PhD, University of Sheffield and Simcyp Limited (a Certara Company)

Michael Voice, PhD, Cypex, Ltd.

Heather Wallace, PhD, University of Aberdeen

Matt Wright, PhD, Newcastle University

Abstract Review Committee

Thomas Baillie, PhD, University of Washington



Neil Kitteringham, PhD, University of Liverpool


Richard Meehan, PhD, University of Edinburgh

Munir Pirmohamed, PhD, University of Liverpool

Colin Suckling, PhD, University of Strathclyde

Geoff Tucker, PhD, University of Sheffield and Simcyp Limited (a Certara Company)


Matt Wright, PhD, Newcastle University

Poster Awards Review Committee

Thomas Baillie, PhD, University of Washington




Edward Morgan, PhD, Emory University


3

Upcoming ISSX Meetings

20th North American ISSX Meeting

October 18 – 22, 2015 Hilton Orlando Bonnet Creek Orlando, Florida, USA Meeting Chairs: Hartmut Derendorf, PhD and Stephan Schmidt, PhD www.issx.org/20NA

11th International ISSX Meeting

June 12 – 16, 2016 Busan Exhibition and Convention Center Busan, Korea Meeting Chair: Jae-Gook Shin, MD, PhD www.issxbusan2016.org

21st North American ISSX Meeting

September 24 – 28, 2017 Rhode Island Convention Center Providence, Rhode Island, USA Meeting Chair: Jashvant Unadkat, PhD

ISSX meetings bring together individuals involved in drug/xenobiotic research in diverse fields including

basic and clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology,

biochemistry, medicinal chemistry, molecular and structural biology, and genetics. Everyone studying or

working in the fields of toxicology, pharmacology, molecular biology, and other areas related to the study

of xenobiotics learn and benefit from attending ISSX meetings. The many benefits of participating in ISSX

meetings include:

• Participate in your choice of multiple short courses designed to deliver a broad-based educational experience.

• Attend outstanding lectures delivered by leading scientists who will share the latest developments in their areas of research.

• Gain recognition and feedback on your research by submitting an abstract and presenting a poster.

• Avail yourself of the many opportunities for substantive conversation and networking with scientists worldwide.

• Meet with our exhibitors who will showcase products and services that could be helpful solutions for you in your research and development.

• Compete for prizes in the student and postdoc poster competition. • Engage in informal social interactions with fellow researchers. • Enjoy the meeting location. ISSX aims to hold meetings in desirable locations that provide

opportunities for attendees to explore cultures and have fun.

Make plans to attend and encourage your colleagues to participate in our upcoming meetings.

4

ISSX Leadership and Staff

President

John Miners Department of Clinical Pharmacology Flinders University School of Medicine Adelaide, Australia

President-Elect/Secretary

Geoff Tucker University of Sheffield and Simcyp Limited (a Certara Company) Sheffield, United Kingdom

Treasurer

Andrew Parkinson XPD Consulting Shawnee, Kansas, USA

Treasurer-Elect

James Halpert University of Connecticut Storrs, Connecticut, USA

Members of Council

Thomas Baillie University of Washington School of Pharmacy Seattle, Washington, USA

Maria Almira Correia University of California San Francisco, California, USA

Ann Daly Newcastle University Institute of Cellular Medicine Newcastle Upon Tyne, United Kingdom

Natalie Hosea Pfizer, Incorporated Cambridge, Massachusetts, USA

Takashi Izumi Daiichi-Sankyo Company, Limited Shinagawa-ku, Tokyo, Japan

Lawrence Marnett Vanderbilt University School of Medicine Nashville, Tennessee, USA

Jasminder Sahi Sanofi Pudong, Shanghai, China

Allan Rettie, Chair, Scientific Affairs Committee Ex-Officio to Council University of Washington Department of Medicinal Chemistry Seattle, Washington, USA

ISSX Staff

Steven Kemp, CAE Executive Director

Zoë Fuller Program Manager

Sarah Langan Program Coordinator

Diana DiAntonio Sr. Program Associate

Ashley Pencak Meeting Manager

Steve Rabeor Exhibits and Sponsorship Sales Manager

Brittany Jackson Exhibits Coordinator

Sunny Patel Accountant

5

mailto:[email protected]













European ISSX Awards

European Scientific Achievement Award Presented to James Brian Houston

The European Scientific Achievement Award is presented to an ISSX member who has

made major scientific contributions to the field within the European region. The

purpose of this award is to recognize meritorious contributions by senior or mid-career

scientists that have had a major impact on research in the field. The 2015 recipient is

James Brian Houston, PhD, Professor of Drug Metabolism and Pharmacokinetics, at the

University of Manchester.

Professor Houston obtained his BSc, PhD, and DSc from the Universities of London

(Queen Mary College), Surrey and Manchester, respectively. He is Professor of Drug Metabolism &

Pharmacokinetics and Director of the Centre for Applied Pharmacokinetic Research at the University of

Manchester. His research interests are in quantitative drug metabolism and pharmacokinetics. He has

provided a lead in the development, evaluation, and implementation of in vitro and in silico approaches to

prediction of human pharmacokinetics promoting the movement away from empirical towards

mechanism-based approaches to prediction. Much of his work is carried out in collaboration with various

pharmaceutical companies. He has supervised more than 50 graduate students. His research publications

in the area of drug metabolite kinetics in vivo and in vitro exceed 200 and are highly cited (with five citation

classics). He has authored/coauthored more than 20 reviews and received more than 100 invitations to

present at national and international meetings. He is a member of the editorial boards of several journals

including Journal of Pharmacology & Therapeutics (1999-2002), Drug Metabolism & Disposition (2002-on)

and Xenobiotica (2008-on), and has served as a director on the governing board of ISSX.

The research by Professor Houston has been highly influential by informing regulatory practice in Europe

and the USA and by establishing and optimizing industrial practices related to drug development,

particularly those related to drug-drug interactions. Professor Houston’s work has also reduced the usage

of animals in research via in vitro – in vivo extrapolation of clearance values as well as other

pharmacokinetic attributes of drug molecules. These techniques have pioneered the movement away from

traditional, essentially empirical approaches towards mechanism-based prediction strategies to avoid the

previously common failure of drugs due to poor PK properties, and to increase the efficiency of clinical

trials. The methodologies have accelerated the discovery and development of better and safer drugs and

have dictated the evolution of best practices recommended by the regulators and have been subsequently

widely-adopted across the pharmaceutical industry.

To recognize and celebrate his substantial contributions to the field of xenobiotic disposition including his

service in the leadership of ISSX and other scientific societies, ISSX proudly awards James Brian Houston

the 2015 European Scientific Achievement Award.

Award Presentation and Lecture: Wednesday, June 24, 2015 | 16:15 – 17:30 | AUDITORIUM A/B/C

6

European ISSX Awards

European New Investigator Award in Honor of Karl J. Netter Presented to Daniel J. Antoine

The 2015 European New Investigator Award in Honor of Karl J. Netter is presented to

an ISSX member who has made significant contributions to the field during their early

career years. The purpose of this award is to encourage and recognize a developing

scientist who is active in the field in Europe.

Dr. Daniel J. Antoine’s research focus is on the development of novel biomarkers of

drug-induced liver injury that can be used to investigate the mechanistic basis of

adverse reactions to drugs as well as provide perspectives on risk-benefit in man.

Recognition for his research has come in the form of the award of a number of academic prizes (British

Toxicology Society Early Career Investigator Award 2013), honorary research fellowships (Harvard Medical

School, USA), a number of invited speaker invitations at international meetings as well as gaining

independent research grant funding from research councils and the pharmaceutical industry.

Dr. Antoine has developed a number of national and international collaborations that have resulted in a

high number of publications for his stage in his career, many of which as first, senior or corresponding

author. Further evidence of Dr. Antoine’s desire to further advance the field of drug safety science is

illustrated by his membership and recent election to a number of committees such as Co-Chair of the

Toxicology Affinity Group for the British Pharmacological Society (2014), Councilor for the IUPHAR Drug

Metabolism and Transporter Executive Board (2014) and the IVTS committee (as Treasurer 2010 –2012).

Dr. Antoine additionally serves as an editorial board member for the journals Pharmacology Research &

Perspective and Biomarkers.

Dr. Antoine has also developed a number of independent collaborations with internationally-recognized

institutions, namely with the Harvard Medical School and the Karolinska Institutet, which has resulted in

the award of honorary research fellowships at these prestigious institutions. In addition to his commitment

to high-quality scientific research, Dr. Antoine is also committed to the teaching and training of future

pharmacological scientists at the University of Liverpool and elsewhere through Masters and Honors

courses.

In recognition of his significant scientific contributions early in his career as well as future strong potential

in the field of foreign compound metabolism and disposition, ISSX proudly bestows the 2015 European

New Investigator Award in Honor of Karl J. Netter to Daniel J. Antoine.

Award Presentation and Lecture: Wednesday, June 24, 2015 | 16:15 – 17:30 | AUDITORIUM A/B/C

CALL FOR NOMINATIONS: 20th NORTH AMERICAN ISSX MEETING AWARDS

www.issx.org/awards/nominations

The 2015 North American Scientific Achievement Award in Honor of Ronald Estabrook, Sponsored by XenoTech, and the 2015 North American New Investigator Award in Honor of James R. Gillette, will be presented at the

20th North American ISSX Meeting in October 2015 in Orlando, Florida.

The awards will include travel support to the meeting. Nominate a deserving member today!

7

General Information

Meeting Venue University of Strathclyde The Technology and Innovation Centre 99 George Street Glasgow G1 1RD United Kingdom Telephone: +44 141 444 7000

Abstracts

Meeting abstracts are available for review in the abstract book provided to attendees at check-in and online at www.issx.org/onlineabstracts.

Information for Invited Speakers An audio-visual technician will be available to assist speakers with loading their presentations. Speakers should bring their presentations on a USB flash drive to their assigned session room no less than 30 minutes prior to the beginning of the session.

ISSX Awards Session The ISSX Awards Session will be held at 16:15 on Wednesday, June 24 in Auditorium A/B/C. The Society’s highest awards presented in the European region will be bestowed to the award winners who will then deliver their award lectures. We encourage all meeting attendees to be present at this important session and to show their support of this year’s celebrated awardees.

Name Badges Name badges are required for admission to the meeting sessions, the exhibit space, and social functions. Badges help facilitate networking and communication with your fellow attendees. If you lose your name badge please visit the registration counter for assistance.

Opening Welcome Reception Fully-registered attendees and registered guests are invited to attend the Opening Welcome Reception on Monday, June 22 from 18:45 – 20:45 in the Level 2 and 3 Foyers. Our exhibitors will be on-hand to meet you and share information about their latest products and services. Hors d’oeuvres will be offered and each attendee will receive one complimentary beverage ticket.

Admission to the Opening Welcome Reception is included in the full-meeting registration fee. Attendees will need their name badges in order to be admitted. Unregistered guests or single-day registrants may purchase an admission ticket for £30 for the reception at the meeting registration counter.

Premier Social Event: Meeting Dinner and Ceilidh Tickets may still be available for this special dinner on Wednesday, June 24 from 18:30 – 22:00.

Join friends and colleagues at the premier social event of the meeting at the Old Fruitmarket of Glasgow which has kept all of its period charm, including its lofty vaulted roof, cast iron columns and balcony, and slender Victorian architecture. Attendees will enjoy a delicious buffet dinner, drinks, and a ceilidh.

The word ceilidh (kay-lee) is derived from the Gaelic word for "gathering" or "party". These days when people think of a ceilidh, they think of a fun-filled night of dancing, good music, and great company!

Wi-Fi Access Complimentary Wi-Fi is available throughout the Technology and Innovation Centre. Access information is available at the registration counter.

8

General Information

Poster Awards Competition and Poster Awards Presentation The awards for best graduate/predoctoral and postdoctoral poster presentations will be held at 12:30 on Thursday, June 25 in Auditorium A/B/C. Meeting attendees may view the twelve finalist poster presentations which will be located in the Level 2 Foyer throughout the meeting.

New Investigators Reception All graduate and postgraduate students as well as postdoctoral scientists still in training who are fully-registered for this meeting are cordially invited to attend a special networking reception on Tuesday, June 23 from 19:30 – 22:00 at Waxy O’Connor’s, located at 44 West George Street. Attendees will receive one drink ticket and may purchase additional drinks with cash. Be sure to attend this event to make new friends and learn about the research interests of your peers.

Meeting Registration Hours Exhibit Hours Monday, June 22 | 08:00 – 19:00 Monday, June 22 | 18:45 – 20:45

Tuesday, June 23 | 07:30 – 17:00 Tuesday, June 23 | 10:30 – 16:00

Wednesday, June 24 | 08:00 – 17:00 Wednesday, June 24 | 10:30 – 16:15

Thursday, June 25 | 08:00 – 17:00 Thursday, June 25 | 11:30 – 12:30

Glasgow City Map

Map data ©2015 Google

9

Scientific Program

Monday, June 22, 2015 08:00 – 19:00 | LEVEL 2 FOYER

Meeting Registration Open

09:00 – 12:30 | AUDITORIUM A

Short Course 1: Mass Spectrometry in Drug Metabolism Studies Co-Chairs: Ian Wilson, Imperial College, London, United Kingdom and Neil Kitteringham, University of Liverpool, Liverpool, United Kingdom

09:00 – 09:45 | SC1.1. LC-MS IN METABOLITE IDENTIFICATION IN HIGH THROUGHPUT DRUG DISCOVERY Anthony Dickie, Evotec (UK) Ltd., Abingdon, United Kingdom

09:45 – 10:30 | SC1.2. DETECTING AND IDENTIFYING REACTIVE METABOLITES Sara Amberntsson, AstraZeneca, Mölndal, Sweden

10:30 – 11:00 | Refreshment Break

11:00 – 11:45 | SC1.3. THE USE OF LC-MS FOR COMPREHENSIVE METABOLITE CHARACTERISATION AND IDENTIFICATION Russell Mortishire-Smith, Waters Corporation, Wilmslow, United Kingdom

11:45 – 12:30 | SC1.4. TIPS, TRICKS AND LC-ICPMS FOR METABOLITE DETECTION AND IDENTIFICATION Ian Wilson, Imperial College, London, United Kingdom

09:00 – 12:30 | AUDITORIUM B/C Short Course 2: Stem Cell Derived Tissues in Toxicology Co-Chairs: Chris Goldring, University of Liverpool, Liverpool, United Kingdom and Matt Wright, Newcastle University, Newcastle upon Tyne, United Kingdom

09:00 – 09:45 | SC2.1. THE APPLICATION OF STEM CELLS IN TOXICOLOGY: WHAT DO WE NEED AND WHY DO WE NEED THEM? Chris Goldring, University of Liverpool, Liverpool, United Kingdom

09:45 – 10:30 | SC2.2. DERIVATION OF CARDIOMYCYTES STEM CELLS AND TOXICITY TESTING Chris Denning, University of Nottingham, Nottingham, United Kingdom


11:00 – 11:45 | SC2.3. STEM CELL-DERIVED RENAL CELLS AND SAFETY ASSESSMENT Daniele Zink, Institute of Bioengineering and Nanotechnology, Singapore

11:45 – 12:30 | SC2.4. HEPATOCYTE STEM CELLS IN TOXICITY TESTING Matt Wright, Newcastle University, Newcastle upon Tyne, United Kingdom

12:30 – 13:30 | LEVEL 3 CONFERENCE ROOMS 6 and 7 Lunch for Short Course Registrants

13:30 – 17:00 | AUDITORIUM A Short Course 3: Physiologically-based Pharmacokinetic Modelling Co-Chairs: Geoff Tucker, University of Sheffield and Simcyp Limited (a Certara Company), Sheffield, United Kingdom and Brian Houston, University of Manchester, Manchester, United Kingdom

13:30 – 14:15 | SC3.1. USE OF PBPK MODELLING FOR FIRST IN HUMAN DOSE PREDICTIONS - INCORPORATION OF UNCERTAINTY IN EXPERIMENTAL DATA AND IN VITRO IN VIVO EXTRAPOLATION STRATEGIES Michael Gertz, F. Hoffmann-La Roche, Basel, Switzerland

14:15 – 15:00 | SC3.2. PBPK CASE STUDIES Karen Rowland-Yeo, Simcyp Limited (a Certara Company), Waterford, Massachusetts, USA


15:30 – 16:15 | SC3.3. PAEDIATRIC PBPK MODELLING Kay Ogungbero, The University of Manchester, Manchester, United Kingdom

16:15 – 17:00 | SC3.4. A EUROPEAN REGULATORY PERSPECTIVE ON PBPK MODELLING Susan Cole, MHRA, London, United Kingdom

13:30 – 17:00 | AUDITORIUM B/C Short Course 4: New Horizons in Mass Spectrometry Co-Chairs: Andy Pitt, Aston University, Birmingham, United Kingdom and Neil Kitteringham, University of Liverpool, Liverpool, United Kingdom

13:30 – 14:15 | SC4.1. NEW APPLICATIONS OF PROTEOMICS IN BIOMEDICAL RESEARCH Andy Pitt, Aston University, Birmingham, United Kingdom

14:15 – 15:00 | SC4.2. IMAGING FOR XENOBIOTICS AND METABOLITES Robert Bradshaw, Sheffield Hallam University, Sheffield, United Kingdom


15:30 – 16:15 | SC4.3. DATA INDEPENDENT ACQUISITION: A NEW ERA FOR QUANTITATIVE PROTEOMICS? Rosalind Jenkins, University of Liverpool, Liverpool, United Kingdom

16:15 – 17:00 | SC4.4. MAKING SENSE OF THE DATA: HOW TO HANDLE LARGE PROTEOMIC AND METABOLOMICS DATASETS Karl Burgess, University of Glasgow, Glasgow, United Kingdom

17:45 – 18:00 | AUDITORIUM A/B/C Opening Session John Miners, President, International Society for the Study of Xenobiotics Ann Daly and Roland Wolf, Co-Chairs, 13th European ISSX Meeting

18:00 – 18:45 | AUDITORIUM A/B/C Opening Keynote Lecture S1. PROTEIN KINASE INHIBITORS: MAJOR DRUGS OF THE 21ST CENTURY

Professor Sir Philip Cohen, University of Dundee, Dundee, United Kingdom

10

Scientific Program 18:45 – 20:45 | LEVELS 2 and 3 FOYERS Opening Welcome Reception / Meet the Exhibitors

Tuesday, June 23, 2015

07:30 – 17:00 | LEVEL 2 FOYER

Meeting Registration Open

07:45 – 08:45 | AUDITORIUM A Industry-Sponsored Symposium: Biopharmaceuticals: Natural Products or Xenobiotic, Friend or Foe? Andrew McEwen, Chief Scientist, Quotient Bioresearch, Ltd.

09:00 – 12:00 | AUDITORIUM A Parallel Symposium 1: Recent Developments in Stem Cell Technology and its Application to Drug Metabolism and Drug Safety Testing Co-Chairs: David Hay, University of Edinburgh, Edinburgh, United Kingdom and Ludovic Vallier, Wellcome Trust - MRC Stem Cell Institute, Cambridge, United Kingdom

09:00 – 09:30 | S2. PLURIPOTENT STEM CELL HEPATOCYTES AND TISSUE ENGINEERING David Hay, University of Edinburgh, Edinburgh, United Kingdom

09:30 – 10:00 | S3. PLURIPOTENT STEM CELL HEPATOCYTES AND CHOLANGIOCYTE MODELS Ludovic Vallier, Wellcome Trust - MRC Stem Cell Institute, Cambridge, United Kingdom

10:00 – 10:30 | S4. RECENT ADVANCES IN DERIVING HEPATOCYTE LIKE CELLS FROM INDUCED PLURIPOTENT STEM CELLS IN DRUG METABOLISM AND TOXICITY STUDIES Tommy B. Andersson, AstraZeneca, Mölndal, Sweden


11:00 – 11:30 | S5. ANIMAL MODELS Stephen Strom, Karolinska Institutet, Stockholm, Sweden

11:30 – 11:45 | P84. REDUCING HUMAN DRUG OVERDOSE USING MICRORNAS Dagmara Szkolnicka, University of Edinburgh, Edinburgh, United Kingdom

11:45 – 12:00 | P18. EFFECT OF DONOR VARIABILITY AND CULTURE CONDITIONS ON PHASE II ACTIVITY IN HUMAN HEPATOCYTES Shalenie P. den Braver-Sewradj, VU University Amsterdam, Amsterdam, The Netherlands

09:00 – 12:00 | AUDITORIUM B/C Parallel Symposium 2: Expanding the Boundaries of PKPD Modelling Co-Chairs: Geoff Tucker, University of Sheffield and Simcyp Limited (a Certara Company), Sheffield, United Kingdom and Brian Houston, University of Manchester, Manchester, United Kingdom

09:00 – 09:30 | S6. SYSTEMS PHARMACOLOGY Meindert Danhof, Leiden University, Leiden, The Netherlands

09:30 – 10:00 | S7. MODELLING IN TOXICITY Oscar Della Pasqua, GlaxoSmithKline, Uxbridge, United Kingdom

10:00 – 10:30 | S8. INCORPORATING TRANSPORTER KINETICS INTO PBPK MODELS Alexandra Galetin, University of Manchester, Manchester, United Kingdom


11:00 – 11:30 | S9. PBPK MODELLING OF mABs Linzhong Li, Simcyp Limited (a Certara Company), Sheffield, United Kingdom

11:30 – 11:45 | P164. SHOULD TOTAL PLASMA DRUG CONCENTRATION BE USED TO PREDICT TRANSPORTER MEDIATED DRUG-DRUG INTERACTIONS FOR HIGHLY PROTEIN BOUND DRUGS? Mark Warren, Optivia Biotechnology Inc., Menlo Park, California, USA

11:45 – 12:00 | P2. SIMULATION STUDY ON CONTRIBUTIONS OF MEMBRANE PERMEABILITY, METABOLIC CLEARANCE, AND EFFLUX TRANSPORT BY P-GLYCOPROTEIN TO INTESTINAL AVAILABILITY USING TRANSLOCATION MODEL Hirotaka Ando, Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan

12:00 – 13:30 | LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch

12:00 – 13:00 | LEVEL 2 FOYER Graduate/Predoctoral Poster Finalist Poster Presentations A1 – A6 Poster Presentations

12:30 – 13:30 | LEVEL 3 FOYER and ROOM 4/5 Poster Session 1: Analytical – Hepatocytes

P1 – P85 Poster Presentations

12:30 – 13:00 | Odd Numbered Posters

13:00 – 13:30 | Even Numbered Posters

13:30 – 15:30 | AUDITORIUM A Parallel Symposium 3: Systems Toxicology Co-Chairs: Paul Watkins, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA and Bob van de Water, Leiden University, Leiden, The Netherlands

13:30 – 14:00 | S10. SYSTEMS MICROSCOPY TO UNRAVEL THE WIRING OF TOXICITY PATHWAYS IN DRUG-INDUCED LIVER INJURY Bob van de Water, Leiden University, Leiden, The Netherlands

14:00 – 14:30 | S11. A QUANTITATIVE SYSTEMS BIOLOGY ANALYSIS OF SIGNAL TRANSDUCTION NETWORKS UNDERLYING DILI Ursula Klingmueller, German Cancer Research Center, Heidelberg, Germany

14:30 – 15:00 | S12. SYSTEMS MODELING APPROACHES TO PREDICT IDIOSYNCRATIC DILI Paul Watkins, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA

15:00 – 15:30 | S13. INTEGRATION OF QSAR AND PK-PD MODELLING IN CARDIAC DRUG SAFETY ASSESSMENT Sebastian Polak, Simcyp Limited (a Certara Company), Sheffield, United Kingdom

11

Scientific Program 13:30 – 15:30 | AUDITORIUM B/C Parallel Symposium 4: Clinical Implementation of Pharmacogenomics Co-Chairs: Ann Daly, Newcastle University, Newcastle upon Tyne, United Kingdom and Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

13:30 – 14:00 | S14. PHARMACOGENOMIC APPROACHES TO TREATMENT OF CYSTIC FIBROSIS Margarida Amaral, Faculty of Sciences of the University of Lisbon, Lisbon, Portugal

14:00 – 14:30 | S15. IMPLEMENTATION OF PHARMACOGENOMICS IN CLINICAL PRACTICE-FOCUS ON EVIDENCE-BASED MEDICINE AND COST-EFFECTIVENESS Munir Pirmohamed, University of Liverpool, Liverpool, United Kingdom

14:30 – 15:00 | S16. IMPORTANCE OF DRUG TRANSPORTER POLYMORPHISMS AND SCOPE FOR CLINICAL IMPLEMENTATION Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

15:00 – 15:30 | S17. APPLICATION OF PHARMACOGENOMICS IN DRUG DEVELOPMENT Martin Armstrong, UCB, Brussels, Belgium

15:30 – 16:00 | LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters

16:00 – 18:30 | AUDITORIUM A Parallel Symposium 5: Role of Drug Transporters: Current and Future Perspectives (an ITC Sponsored Symposium) Co-Chairs: Donald Tweedie, Boehringer Ingelheim, Ridgefield, Connecticut, USA and Brian Houston, University of Manchester, Manchester, United Kingdom

16:00 – 16:30 | S18. APPLYING THE EU DDI RECOMMENDATIONS ON TRANSPORTERS – MPA EXPERIENCES AND FUTURE EXPECTATIONS Eva Gil Berglund, Medical Products Agency, Uppsala, Sweden

16:30 – 17:00 | S19. SUBSTRATE/INHIBITION ASSAYS AND PREDICTION OF DDIs Christoph Funk, F. Hoffmann-La Roche Ltd., Basel, Switzerland

17:00 – 17:30 | S20. PREDICTIONS OF CELLULAR DRUG BINDING AND IMPLICATIONS FOR INTRACELLULAR DRUG CONCENTRATIONS AND EFFECTS Par Matsson, Uppsala University, Uppsala, Sweden

17:30 – 18:00 | S21. N1-METHYLNICOTINAMIDE: AN ENDOGENOUS PROBE FOR DRUG INTERACTIONS BY RENAL CATION TRANSPORTERS? Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

18:00 – 18:30 | POST-SYMPOSIUM DISCUSSION: ITC, CURRENT STATUS AND FUTURE DIRECTIONS Donald Tweedie, Boehringer Ingelheim, Ridgefield, Connecticut, USA

16:00 – 18:00 | AUDITORIUM B/C Parallel Symposium 6: Advances in Pathways of Chemically-induced Oxidative Stress and DNA Damage Co-Chairs: John Hayes, University of Dundee, Dundee, United Kingdom and Ken Tew, Medical University of South Carolina, Charleston, South Carolina, USA

16:00 – 16:30 | S22. CONTROL OF REDOX HOMEOSTASIS BY THE NRF2 REGULATORY NETWORK John Hayes, University of Dundee, Dundee, United Kingdom

16:30 – 17:00 | S23. REGULATION OF PROTEIN FUNCTION FOLLOWING S-GLUTATHIONYLATION Ken Tew, Medical University of South Carolina, Charleston, South Carolina, USA

17:00 – 17:30 | S24. THE REDOX CHEMISTRY OF ANTIOXIDANTS Claus Jacob, University of Saarland, Saarland, Germany

17:30 – 18:00 | S25. CONTROL OF H2O2 TRANSPORT IN AND BETWEEN CELLS Roberto Sitia, Division of Genetics and Cell Biology, Milan, Italy

18:30 – 19:30 | GLASGOW CITY CHAMBERS Civic Reception This is a ticketed event. See map on page 9 for directions.

19:30 – 22:00 | WAXY O’CONNOR’S New Investigators Networking Reception This event is open to students and new investigators. See map on page 9 for directions.

20:00 – 22:00 | THE CORINTHIAN CLUB ISSX President’s Reception By invitation.

Wednesday, June 24, 2015 08:00 – 17:00 | LEVEL 2 FOYER Meeting Registration Open

09:00 – 12:00| AUDITORIUM A Parallel Symposium 7: Humanised Animal Models in Drug Development Co-Chairs: Colin Henderson, University of Dundee, Dundee, United Kingdom and Frank Gonzalez, National Cancer Institute, Bethesda, Maryland, USA

09:00 – 09:30 | S26. HUMANISED MOUSE MODELS OF DRUG METABOLISM Colin Henderson, University of Dundee, Dundee, United Kingdom

09:30 – 10:00 | S27. MOUSE MODELS FOR ELUCIDATION OF CYP2D6 AND CYP2C19 FUNCTION IN THE DEVELOPING AND ADULT BRAIN Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden

10:00 – 10:30 | S28. KNOCKOUT AND HUMANISED MOUSE MODELS FOR DETOXIFYING PROTEINS Alfred Schinkel, The Netherlands Cancer Institute, Amsterdam, The Netherlands


12

Scientific Program 11:00 – 11:30 | S29. LIPOPROTEIN AND BILE ACID PROFILES IN FRG MICE WITH HUMANISED LIVERS Ewa Ellis, Karolinska Institutet, Stockholm, Sweden

11:30 – 11:45 | P131. A PHARMACOKINETIC MODELING APPROACH TO PREDICT THE CONTRIBUTION OF ACTIVE METABOLITES TO HUMAN EFFICACIOUS DOSE Iain Martin, Merck, Boston, Massachusetts, USA

11:45 – 12:00 | P136. OPTIONS TO BOOST EXPOSURE OF ‘PROOF OF CONCEPT’ TOOL COMPOUNDS IN RODENTS TO ACCELERATE EARLY STAGE RESEARCH Lesley Murray, Genentech Inc., South San Francisco, California, USA

09:00 – 12:00 | AUDITORIUM B/C Parallel Symposium 8: The Contribution of the Gut Microbiome to Drug Metabolism, Drug Interactions and Drug Toxicity Co-Chairs: Heather Wallace, University of Aberdeen, Aberdeen, United Kingdom and Elaine Holmes, Imperial College London, London, United Kingdom

09:00 – 09:30 | S30. MICROBIOME METABOLOMICS Elaine Holmes, Imperial College London, London, United Kingdom

09:30 – 10:00 | S31. IMPACT OF HOST-MICROBIAL INTERACTIONS ON TOXICOKINETICS OF TACRINE Eric Chan, National University of Singapore, Singapore

10:00 – 10:30 | S32. REGULATION OF HOST METABOLISM BY THE GUT MICROBIOME THROUGH THE ARYL-HYDROCARBON-RECEPTOR Sven Pettersson, Karolinska Institutet, Stockholm, Sweden and Nanyang Technological University, Singapore


11:00 – 11:30 | S33. THE IMPACT OF THE METAEXOMETABOLOME ON GUT FUNCTION AND HEALTH – A CASE STUDY OF SHORT CHAIN FATTY ACIDS Bernard Corfe, University of Sheffield, Sheffield, United Kingdom

11:30 – 11:45 | P40. ON-LINE ELECTROCHEMISTRY/MASS SPECTROMETRY (EC/MS) – A POWERFUL TOOL FOR THE PREDICTION OF DRUG OXIDATIVE METABOLISM REACTIONS AND THEIR MOLECULAR MECHANISM Agnieszka Potęga, Gdańsk University of Technology, Gdańsk, Poland

11:45 – 12:00 | P69. IN VITRO ASSESSMENT OF SKIN METABOLISM: COMPARISON OF METHODS AND IMPLICATIONS FOR WIDER APPLICATION Katie Plant, Cyprotex, Macclesfield, United Kingdom


12:00 – 13:00 | LEVEL 2 FOYER Postdoctoral Poster Finalist Poster Presentations A7 – A12 Poster Presentations

12:30 – 13:30 | LEVEL 3 FOYER and ROOM 4/5 Poster Session 2: In silico – Transporters

P86 – P166 Poster Presentations



13:30 – 15:30 | AUDITORIUM A Parallel Symposium 9: Epigenomics in Drug Metabolism and Disease Co-Chairs: Richard Meehan, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom and Jonathan Moggs, Novartis, Basel, Switzerland

13:30 – 14:00 | S34. EPIGENOMICS – IMPACT FOR TRANSLATIONAL SCIENCES Remi Terranova, Novartis, Basel, Switzerland

14:00 – 14:30 | S35. 5hmC – TISSUE SPECIFICITY AND MODULATION BY XENOBIOTICS John Thomson, University of Edinburgh, Edinburgh, United Kingdom

14:30 – 15:00 | S36. GENETIC-EPIGENETIC INTERACTIONS AND IMPLICATIONS FOR GENOME STABILITY/FUNCTION Thomas Carell, Ludwig Maximilian University of Munich, Munich, Germany

15:00 – 15:30 | S37. SPATIAL ORGANIZATION OF THE NUCLEUS AND INFLUENCE ON HUMAN DISEASE Wendy Bickmore, MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom

13:30 – 15:30 | AUDITORIUM B/C Parallel Symposium 10: Proteins as Targets for Covalent Modification by Xenobiotics: Therapeutic Opportunities versus Toxicological Risk Co-Chairs: Thomas Baillie, University of Washington, Seattle, Washington, USA and Kevin Park, University of Liverpool, Liverpool, United Kingdom

13:30 – 14:00 | S38. PHARMACOLOGICAL, PHYSIOLOGICAL, AND PATHOLOGICAL CONSEQUENCES OF DRUG BIOACTIVATION AND COVALENT BINDING Kevin Park, University of Liverpool, Liverpool, United Kingdom

14:00 – 14:30 | S39. REACTIVE DRUG METABOLITES AND TARGETED COVALENT INHIBITORS: A RISK-BENEFIT PERSPECTIVE Thomas Baillie, University of Washington, Seattle, Washington, USA

14:30 – 15:00 | S40. (DMPK) CHALLENGES IN DEVELOPING AZD9291: AN IRREVERSIBLE INHIBITOR OF EGFR SELECTIVE FOR SENSITISING AND T790M RESISTANCE MUTATIONS Peter Ballard, AstraZeneca, Cheshire, United Kingdom

15:00 – 15:30 | S41. INHIBITORS OF CATHEPSIN C: NOT YOUR TYPICAL ORAL SMALL MOLECULES Catherine Booth-Genthe, GlaxoSmithKline, Collegeville, Pennsylvania, USA

15:30 – 16:15 | LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters

16:15 – 17:30 | AUDITORIUM A/B/C Presentation of ISSX Awards and Award Lectures

16:15 – 16:55 | European Scientific Achievement Award James Brian Houston, PhD

16:55 – 17:30 | European New Investigator Award in Honor of Karl J. Netter Daniel J. Antoine, PhD

13

Scientific Program 18:30 – 22:00 | OLD FRUITMARKET Meeting Dinner and Ceilidh This is a ticketed event; tickets may be available for purchase at the registration desk. See map on page 18 for directions.

Thursday, June 25, 2015 08:00 – 17:00 | LEVEL 2 FOYER Meeting Registration Open

09:00 – 11:30 | AUDITORIUM A Parallel Symposium 11: Predicting Human Responses During Drug Discovery and Development Co-Chairs: Roland Wolf, University of Dundee, Dundee, United Kingdom and Peter Moldeus, Karolinska Institutet, Stockholm, Sweden

09:00 – 09:30 | S42. APPLICATION OF IN VIVO REPORTERS FOR STRESS RESPONSES IN DRUG DEVELOPMENT Roland Wolf, University of Dundee, Dundee, United Kingdom

09:30 – 10:00 | S43. PREDICTING HUMAN RESPONSES TO DRUGS: CHALLENGES AND OPPORTUNITIES OF IN VITRO APPROACHES Ruth Roberts, AstraZeneca, Wilmslow, United Kingdom

10:00 – 10:30 | S44. ESTABLISHING POTENTIAL SAFETY LIABILITIES IN EARLY DRUG DEVELOPMENT Bill Pennie, Takeda, Cambridge, Massachusetts, USA

10:30 – 11:00 | S45. THE APPLICATION OF EPIGENOME AND KINOME-BASED BIOASSAYS FOR RISK ASSESSMENT Ivonne Rietjens, Wageningen University, Wageningen, The Netherlands

11:00 – 11:15 | P29. APPLICATION OF A MOUSE LINE HUMANISED FOR HPXR/CAR/CYP3A4/CYP3A7/CYP2D6/CYP2C9 TO INVESTIGATE THE REVERSIBLE AND TIME-DEPENDENT INHIBITION OF MIDAZOLAM 1’-HYDROXYLATION Yury Kapelyukh, University of Dundee, Dundee, United Kingdom

11:15 – 11:30 | P82. HUMAN PLURIPOTENT STEM CELL-DERIVED HEPATOCYTES WITH SUBSTANTIAL METABOLIC FUNCTIONALITY AND ADULT CHARACTERISTICS ARE HIGHLY SUITABLE FOR TOXICITY TESTING Barbara Küppers-Munther, Takara Bio Europe (former Cellartis), Göteborg, Sweden

09:00 – 11:30 | AUDITORIUM B/C Parallel Symposium 12: Conjugating Enzymes and Hydrolases in Endogenous and Foreign Compound Metabolism Co-Chairs: Michael Arand, University of Zurich, Zurich, Switzerland and John Miners, Flinders University, Adelaide, Australia

09:00 – 09:30 | S46. A HYPERACTIVE mEH VARIANT: SEVERE TRADE-OFF FOR FASTER DETOX Anne Marowsky, University of Zurich, Zurich, Switzerland

09:30 – 10:00 | S47. DDIs INVOLVING GLUCURONIDATED DRUGS John Miners, Flinders University, Adelaide, Australia

10:00 – 10:30 | S48. ROLE OF SULTs IN METABOLIC ACTIVATION Hansruedi Glatt, German Institute of Human Nutrition, Berlin, Germany

10:30 – 11:00 | S49. CARBOXYLESTERASE 1 – SUBSTRATES, REGULATION OF ENZYME ACTIVITY AND PHARMACOGENETICS Henrik Rasmussen, Institute of Biological Psychiatry, Roskilde, Denmark

11:00 – 11:15 | P77. REGULATION OF UDP GLUCURONOSYLTRANSFERASE 2B15 AND 2B17 EXPRESSION BY MICRO-RNAS IN PROSTATE CELLS Peter Mackenzie, Flinders University, Adelaide, Australia

11:15 – 11:30 | P17. A NOVEL APPROACH IN MEASURING PROTEIN S-GLUTATHIONYLATION IN STRESS RESPONSE SIGNALLING David McGarry, University of Dundee, Dundee, United Kingdom


12:30 – 13:00 | AUDITORIUM A/B/C Presentation of ISSX Poster Awards

13:00 – 15:00 | AUDITORIUM A/B/C Plenary Session: Inflammation: Effects on Drug Metabolism and Disease Aetiology Co-Chairs: Kathie Knights, Flinders University, Adelaide, Australia and Eddie Morgan, Emory University, Atlanta, Georgia, USA

13:00 – 13:30 | S50. INFLAMMATORY REGULATION OF HUMAN DRUG METABOLIZING ENZYMES Ulrich Zanger, Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

13:30 – 14:00 | S51. REGULATION OF DRUG TRANSPORTERS IN INFLAMMATION: IMPACT ON DRUG DISPOSITION Micheline Piquette-Miller, University of Toronto, Toronto, Ontario, Canada

14:00 – 14:30 | S52. ROLE OF NO IN INFLAMMATORY REGULATION OF DRUG METABOLIZING ENZYMES Eddie Morgan, Emory University, Atlanta, Georgia, USA

14:30 – 15:00 | S53. INFLAMMATION AND LIVER DISEASE Percy Knolle, Technische Universität München, München, Germany

15:00 – 15:45 | AUDITORIUM A/B/C Closing Plenary Lecture Frank Gonzalez, National Cancer Institute, Bethesda, Maryland, USA

15:45 – 16:00 | AUDITORIUM A/B/C Closing Remarks Meeting Co-Chairs: Ann Daly and Roland Wolf

John Miners, President, International Society for the Study of Xenobiotics

Jae-Gook Shin, 11th

International ISSX Meeting Chair

Uwe Fuhr, 14th

European ISSX Meeting Chair

14

Poster Information

Poster Awards Competition Poster Presentations | LEVEL 2 FOYER

Poster

Session

Poster

Set-Up

Poster

Tear-Down*

Poster

Presentation

Dates and Times

Poster Awards

Presentation

Graduate / Predoctoral

Posters A1 – A6 LEVEL 2 FOYER

Tuesday, June 23

07:30 – 09:00

LEVEL 2 FOYER

Thursday, June 25

13:00 – 14:00

LEVEL 2 FOYER

Tuesday, June 23

12:00 – 13:00

AUDITORIUM

A/B/C

Thursday, June 25

12:30 – 13:00 Postdoctoral

Posters A7 – A12

LEVEL 2 FOYER

Wednesday, June 24

12:00 – 13:00

*All posters must be removed by 14:00 on Thursday, June 25. ISSX is not responsible for posters remaining after 14:00.

General Poster Abstracts Presentations | LEVEL 3 FOYER and ROOM 4/5

Poster

Session

Poster

Set-Up

Poster

Tear-Down**

Poster Presentation

Dates and Times

Session 1

Analytical – Hepatocytes Posters P1 – P85

LEVEL 3 FOYER

and ROOM 4/5

Tuesday, June 23

07:30 – 09:00

LEVEL 3 FOYER

and ROOM 4/5

Thursday, June 25

12:00 – 13:00

LEVEL 3 FOYER and ROOM 4/5

Tuesday, June 23



Session 2

In silico – Transporters Posters P86 – P166

LEVEL 3 FOYER and ROOM 4/5

Wednesday, June 24



**All posters must be removed by 13:00 on Thursday, June 25. ISSX is not responsible for posters remaining after 13:00.

View the poster numbering scheme on the following page.

15

Poster Information

Poster Number Quick Reference Guide:

Finalists in the Graduate / Pre-doctoral Poster Awards Competition A1 – A6

Finalists in the Postdoctoral Poster Awards Competition A7 – A12

Absorption P1 – P2

Analytical P3 – P6

Bioavailability P7 – P9

Clearance Prediction P10 – P16

Conjugation Reactions and Enzymes P17 – P19

Cytochrome P450 P20 – P28

Differences in Metabolism (species, gender, age, diseases) P29 – P32

Disposition P33 – P38

Drug Discovery and Development P39 – P42

Drug Interaction P43 – P58

Enzyme Induction P59 – P63

Enzyme Inhibition/Inactivation P64 – P68

Extrahepatic Metabolism P69

Gene Expression and Regulation P70 – P79

Genomics / Metabolomics / Proteomics P80 – P81

Hepatocytes P82 – P85

In silico P86 – P89

In vitro Techniques P90 – P93

Mechanisms of Xenobiotic Toxicities P94 – P105

Metabolic Profiling P106 – P111

Metabolism P112 – P120

Non-P450 Phase I Enzymes P121 – P122

Pharmacogenetics P123 – P130

Pharmacokinetics and Pharmacodynamics P131 – P140

Receptors / Nuclear Receptors P141 – P145

Transporters P146 – P166

Submit an Abstract for the 20th North American ISSX Meeting

We encourage all those involved in the fields of metabolism, pharmacology, toxicology, molecular biology and other related disciplines to consider submitting an abstract for a poster presentation at the 20th North American ISSX Meeting.

This meeting will provide a wonderful opportunity to showcase work being done in a variety of areas and to network with other researchers.

Abstract authors will have an opportunity to submit abstracts to the general abstract poster sessions and student authors can compete in the poster awards competition open to graduate/predoctoral and postdoctoral students. The call for abstracts closes Friday, July 10, 2015.

Visit www.issx.org/20na/abstracts to review the guidelines and submit your work.

16

Industry-Sponsored Symposium Industry-Sponsored Symposia (ISS) are commercially-supported educational sessions held in conjunction with the 13th European ISSX Meeting. This session has been approved for presentation at our meeting. All attendees are invited to enjoy a light breakfast and the education this session provides.

Tuesday, June 23, 2015

07:45 – 08:45 | AUDITORIUM A Presented by Quotient Bioresearch, Ltd. Biopharmaceuticals: Natural Products or Xenobiotic, Friend or Foe? Andrew McEwen, Chief Scientist, Quotient Bioresearch, Ltd.

Biopharmaceuticals (biologics) are broadly defined as medicinal products manufactured in, extracted from, or semi-synthesised from biological sources. They are seen as different from traditional pharmaceutical products (small molecules) and whilst there is a requirement to undertake laboratory and animal testing before they can be administered to man, such studies necessitate a science based, case-by case evaluation.

Regulatory guidelines, notably ICH S6 refer to the difficulty of providing a standard guidance for PK and TK studies for biologics, whilst noting the potential utility of both single and repeat dose PK studies along with tissue distribution studies. Classical biotransformation investigations as required for small molecules are considered unnecessary due to well understood catabolism to natural products, mainly amino acids, and there is no requirement to determine a mass balance to elicit excretion pathways. It has also been reported that current analytical methods have a limited capacity to separate and identify catabolites, and that even if formed these catabolites would have limited pharmacological or toxicological activity.

13th European ISSX Meeting Sponsor

ISSX thanks Solvo Biotechnology for their sponsorship of this meeting.

ISSX Corporate Partners

ISSX thanks these corporate sponsors for their support of ISSX this year.

17

Join fellow attendees for a delicious dinner and dance in a unique venue that presents Glasgow’s

history and charm. Set to begin at 18:30 on Wednesday, June 24, this is the premier social event of

the meeting and no better place for attendees to catch up with old friends and make new

acquaintances. A separate registration fee of $145 applies. Tickets may still be available at the ISSX

registration counter in the Level 2 Foyer. Only blocks away from the Technology and Innovation

Centre, this event can’t be missed!

18

Exhibitor Directory The support of the many vendors participating in our meeting exhibition significantly helps ISSX to organize and host leading scientific meetings. Please visit and spend time with each exhibiting company to learn how their products and services can help you with your research.

BIOPREDIC International Booth 103

BIOPREDIC International provides to industrial and academic researchers human and animal tissues, cells, fractions and reagents such as high quality hepatocytes and other derivatives of the liver, skin products, blood products and other biological fluids and non- standard animal products. These reagents are used for in vitro tests in pharmaceutical, cosmetic and chemical industry. BIOPREDIC International holds a portfolio of patents and licenses on the human liver cell line HepaRG®.

BioreclamationIVT Booth 101

BioreclamationIVT is a worldwide provider of biological and in vitro products to pharmaceutical and biotechnology organizations. Our company specializes in control animal, normal human and disease state human biological matrices for use in drug discovery along with hepatocyte and microsome products used in the preclinical industry.

BioReliance Booth 200

BioReliance offers a wide portfolio of innovative products and specialized services for preclinical drug metabolism and safety testing. Using our expertise in functional genomics we have developed novel genetically-modified cell based assays and tools to increase predictability and improve drug development success.

Corning Booth 502

Corning Incorporated offers integrated solutions to support life sciences and accelerate drug discovery with products and Contract Research Services for the in vitro analysis of xenobiotic metabolism and drug transport. Products include Corning® Gentest™ Hepatocytes, Tissue Fractions, Transporter Systems, Corning Supersomes™ Enzymes, and Corning Gentest Contract Research Services.

Covance Booth 104

Covance Inc., the drug development business of Laboratory Corporation of America® Holdings (LabCorp®) headquartered in Princeton, New Jersey, is the world's most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®. Information on Covance's solutions can be obtained through its website at www.covance.com.

Cypex Booth 604

Cypex manufactures high quality recombinant CYPs from a range of species along with other enzymes such as AOX, ALDH, GSTs and SULTs as well as offering antibodies, purified CYPs, substrates and inhibitors. Services include CYP inhibition screening, protein expression and metabolite generation. Products and services are covered by an ISO9001:2008 accredited quality assurance system.

19

Exhibitor Directory

Cyprotex Discovery Ltd Booth 105

Cyprotex was founded in 1999 and has 100+ scientists specialising in in vitro and in silico ADME-Tox. Cyprotex performs both screening and regulatory (metabolite profiling, transporters, enzyme interactions etc.) work, and prides itself on our proprietary ADME-Tox technologies and added value (planning, interpretation) returned to customers through scientist-to-scientist communication.

Eurofins Pharma Discovery Services Booth 304

For over 40 years, Eurofins Pharma Discovery Services has been a trusted CRO supporting drug discovery from HTS to preclinical stages. Uniting the expertise of Cerep, Panlabs & Discovery Services, we support efficacy, safety & PK testing with our products and in vitro pharmacology, phenotypic, ADME-Tox and in vivo services.

HTG Molecular Diagnostics Booth 202

Headquartered in Tucson, Arizona, HTG Molecular Diagnostics’ mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.

Huntingdon Life Sciences/Harlan Laboratories Booth 306

Huntingdon Life Sciences/ Harlan Laboratories is an international CRO offering a comprehensive range of development services to pharmaceutical and biopharmaceutical companies. We help our customers develop safe and effective new compounds. Our Research Models and Services operating group provides high-quality research models and lab animal diets with support services worldwide.

Hurel Corporation Booth 503

HµREL® researches, develops, and commercializes products and services based on its patent-pending cell-based tissue constructs. Currently, Hurel offers primary hepatic co-culture models of the human, non-human primate, dog and rat species in almost any format; Hurel recently introduced a suite of services featuring Hurel’s robust co-culture platform. HurelTox™ multi-parametric toxicity screening service and Hurelflux™ patent-pending direct method to measure biliary efflux transporters. The Company’s HµRELflow™ multi-tissue microfluidic platform is currently in beta-test stage.

Informa Healthcare Booth 302

Informa Healthcare publishes more than 180 peer-reviewed journals spanning the complete spectrum of drug discovery to clinical medicine – from bench to bedside and beyond. If you are looking to submit research, then we have a publication to match. As of 2015 Informa Healthcare is part of the Taylor & Francis Group. Visit www.informahealthcare.com for more information about our range of titles.

20

Exhibitor Directory

InSphero, Inc. Booth 204

InSphero is the leading provider of 3D InSight™ Microtissues and screening services to the pharmaceutical, cosmetics and chemical industry. Our assay-ready 3D InSight™ Liver Microtissues (human, rat, HepG2, dog, cyno, minipig) enable more biologically relevant & predictive in vitro compound assessment, including long-term, low-dose toxicity and assessment of transporter function.

Lablogic Systems Booth 106

LabLogic Systems is a worldwide market leader in the supply of LIMS and chromatography data systems to pharmaceutical, academic, nuclear medicine and contract research laboratories. Our products include Debra LIMS for radiolabelled metabolism studies, radiochromatography detectors and software for HPLC and TLC, liquid scintillation and gamma counters.

Lhasa Limited Booth 107

Educational charity and active research organisation with an enviable reputation for collaborative work within different industry sectors; Lhasa Limited is a developer of prediction software and chemical databases. Derek Nexus: Toxicity prediction; Meteor Nexus: Metabolic fate prediction; Sarah Nexus: Toxicity prediction; Vitic Nexus: Chemical database; Zeneth: Chemical degradation prediction

Optivia Biotechnology Booth 505

Optivia Biotechnology is a leader in transporter biology research and services. Providing an array of transporter assays and offering comprehensive databases and models to help in the discovery and development of drugs with improved safety and efficacy.

PRIMACYT Cell Culture Technology GmbH Booth 602

PRIMACYT is a manufacturer of primary human and animal cells, media and consumables for in vitro technologies. We offer fresh and cryopreserved liver cells from all relevant species in pharmacology and toxicology. We are GLP certified, act as a contract researcher and serve as reference laboratory for the European Union.

QPS, LLC Booth 601

QPS is a GLP/GCP-compliant CRO that supports discovery, preclinical, and clinical drug development. We provide quality services in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research to clients worldwide. Our 30+ regional laboratories, clinical facilities and offices are located in North America, Europe, India and Asia. For more information, visit http://www.qps.com.

Qualyst Transporter Solutions, LLC Booth 600

Qualyst Transporter Solutions is the world’s exclusive provider of hepatic drug transporter products and contract research services, utilizing the proprietary B-CLEAR® technology, that support drug discovery and development. Our integrated hepatic model can investigate: intracellular concentration, transporter uptake and efflux mechanisms of clearance, drug transporter interactions related to induction and inhibition, and hepatic-related toxicities such as cholestasis and hyperbilirubinemia.

21

Exhibitor Directory

Quotient Bioresearch Booth 300

Quotient Bioresearch is a leading global CRO providing early stage and specialist drug development services to clients worldwide. We provide tailored and integrated solutions for pharmaceutical, biotechnology and agrochemical clients, using state-of-the-art technologies underpinned by unparalleled scientific, medical, chemical and biological expertise. For additional information contact us at [email protected].

Simulations Plus, Inc. Booth 206

GastroPlus™ sets the standard for PBPK/PD modeling for different administration routes in humans and animals, plus population simulations and DDI capabilities. DDDPlus™ and MembranePlus™ offer simulations of in vitro dissolution and permeability experiments. The ADMET Design Suite™ mines compound libraries, designs new molecules, and virtually screens structures for >140 ADMET properties.

SOLVO Biotechnology Booth 504

Drug Transporter Services and Products from the Expert! SOLVO Biotechnology is the leading provider of transporter assays Worldwide, since 1999. With over 100 solutions, we support your in-house or outsourced projects with high quality products or services, including FDA-, EMA, PMDA-ready reports. Please visit our booth #504 and www.solvo.com!

tebu-bio Booth 102

tebu-bio supplies the most innovative range of Services & Reagents for Life Sciences throughout Europe. Customers enjoy local customer service and support through tebu-bio’s European network of 9 offices. Specialists are always on hand to offer expert advice on choosing and using the best products suited to your research projects.

XenoTech, LLC Booth 100

XenoTech, LLC is a global Contract Research Organization with unparalleled experience and proven expertise from discovery through clinical support, providing cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting. Visit www.xenotechllc.com for more information.

22

Notes

23

Notes

24

Technology and Innovation Centre Floor Plan

LEVEL 2: Registration, Poster Awards Finalists Posters, Exhibits 100 – 306, Auditorium A

LEVEL 3: Poster Sessions 1 and 2, Exhibits 500 – 601, Auditorium B/C

The 20th North American ISSX Meeting will bring together individuals who are actively working

on drug/xenobiotic research in diverse fields including basic and clinical pharmacology and

therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal

chemistry, molecular and structural biology, and genetics.

Visit www.issx.org/20na to learn about this exciting meeting and register today.

An International ISSX Meeting is a meeting for the entire Society that offers a broad ranging

program to serve the interests of all its scientific and geographical constituencies. Busan is the

second largest city in Korea. Located in the Southern part of the Korean peninsula, Busan is

easily accessible directly from 10 countries and also via Seoul from all over the world.

Visit www.issxbusan2016.org to make plans for attending this meeting in 2016.

SAVE THE DATE

Documents

13th European ISSX Meeting Program